Workflow
Pulmonx(LUNG)
icon
Search documents
Pulmonx(LUNG) - 2024 Q1 - Quarterly Report
2024-05-03 20:13
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39562 PULMONX CORPORATION (Exact name of registrant as specified in its charter) Delaware 77-0424412 (State or other jur ...
Pulmonx(LUNG) - 2024 Q1 - Earnings Call Transcript
2024-05-02 01:08
Pulmonx Corporation (NASDAQ:LUNG) Q1 2024 Earnings Call Transcript May 1, 2024 4:30 PM ET Company Participants Elizabeth Sparicio - Investor Relations at the Gilmartin Group Steve Williamson - President & Chief Executive Officer Mehul Joshi - Chief Financial Officer Conference Call Participants Jon Young - Canaccord Rick Wise - Stifel Vik Chopra - Wells Fargo Operator Good day, and thank you for standing by. Welcome to Pulmonx Q1 2024 Earnings Conference Call. At this time, all participants are in a listen- ...
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research· 2024-05-01 23:05
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.42 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.28%. A quarter ago, it was expected that this company would post a loss of $0.39 per share when it actually produced a loss of $0.36, delivering a surprise of 7.69%.Over the last four quarters, the company has surpa ...
Pulmonx(LUNG) - 2023 Q4 - Annual Report
2024-02-27 21:07
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-39562 PULMONX CORPORATION (Exact name of registrant as specified in its charter) Delaware 77-0424412 (State or other jurisdiction of incorporation or organizati ...
Pulmonx(LUNG) - 2023 Q4 - Earnings Call Presentation
2024-02-22 02:01
© 2024 Pulmonx Corporation1 © 2024 Pulmonx Corporation | --- | --- | --- | --- | |----------------------------------------------------------------------------|-------|-------|----------------------------------------------------------------| | | | | | | Large Market | | | Broadly Reimbursed | | $12B opportunity for severe emphysema | | | In global guidelines & reimbursed in US, Europe and Australia | | | | | | | Precision Treatment | | | Global Footprint | | Proprietary patient selection technology & minimal ...
Pulmonx(LUNG) - 2023 Q4 - Earnings Call Transcript
2024-02-22 02:01
Pulmonx Corporation. (NASDAQ:LUNG) Q4 2023 Earnings Conference Call February 21, 2024 4:30 PM ET Company Participants Laine Morgan - Investor Relations, Gilmartin Group LLC Glendon French - President and Chief Executive Officer John McKune - Interim Chief Financial Officer and Vice President Corporate Controller Conference Call Participants Jason Bednar - Piper Sandler Rick Wise - Stifel Jon Young - Canaccord Operator Good day and thank you for standing by. Welcome to the Pulmonx Fourth Quarter and Full Yea ...
Pulmonx(LUNG) - 2023 Q3 - Quarterly Report
2023-11-03 20:04
WASHINGTON, D.C. 20549 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39562 PULMONX CORPORATION (Exact name of registrant as specified in its charter) Delaware 77-0424412 (State or other ...
Pulmonx(LUNG) - 2023 Q3 - Earnings Call Transcript
2023-10-31 00:37
Pulmonx Corporation (NASDAQ:LUNG) Q3 2023 Earnings Conference Call October 30, 2023 4:30 PM ET Company Participants Dorothy Morgan - Investor Relations, Gilmartin Group LLC Glendon French - President and Chief Executive Officer John McKune - Interim Chief Financial Officer and Vice President Corporate Controller Conference Call Participants Jason Bednar - Piper Sandler Frederick Wise - Stifel Financial Corp. Larry Biegelsen - Wells Fargo Joanne Wuensch - Citi Jon Young - Canaccord Alex Nowak - Craig-Hallum ...
Pulmonx(LUNG) - 2023 Q2 - Earnings Call Transcript
2023-08-06 06:20
Pulmonx Corporation (NASDAQ:LUNG) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Dorothy Morgan - Investor Relations, Gilmartin Group LLC Glendon French - President and Chief Executive Officer Derrick Sung - Chief Financial Officer Conference Call Participants Rick Wise - Stifel Financial Corp. Jason Bednar - Piper Sandler Zachary Day - Canaccord Genuity Group Inc. Operator Thank you for standing by. Welcome to the Pulmonx Second Quarter 2023 Earnings Conference Call. At thi ...
Pulmonx(LUNG) - 2023 Q2 - Quarterly Report
2023-08-04 20:21
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39562 PULMONX CORPORATION (Exact name of registrant as specified in its charter) Delaware 77-0424412 (State or other jurisdiction of incorporation or organization) (I.R. ...